Filtros de búsqueda

Lista de obras de Luca Gianni

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

artículo científico publicado en 2017

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

artículo científico publicado en 2013

30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study

artículo científico publicado en 2005

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.

artículo científico publicado en 2016

A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas.

artículo científico publicado en 2016

A phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancer

scientific article published on 01 June 2012

A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma

artículo científico publicado en 2018

A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer

artículo científico publicado en 2012

A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer.

artículo científico publicado en 2004

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer

artículo científico

Accurate data processing improves the reliability of Affymetrix gene expression profiles from FFPE samples

artículo científico publicado en 2014

Adjuvant trastuzumab in early breast cancer.

artículo científico publicado en 2006

An interview with Luca Gianni

artículo científico publicado en 2010

An unmet need: tailoring extended adjuvant endocrine therapy

artículo científico publicado en 2013

Anthracycline cardiotoxicity

scientific article published on 01 January 2008

Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes

artículo científico publicado en 2007

Anthracycline cardiotoxicity: from bench to bedside

artículo científico publicado en 2008

Anthracyclines

artículo científico publicado en 2002

Anthracyclines

artículo científico publicado en 2003

Anthracyclines and early breast cancer: the end of an era?

artículo científico publicado en 2009

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity

artículo científico publicado en 2004

Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial

scientific article published on 01 February 2019

BOLERO-3 results: pharmacological activity or pharmacokinetic effect?--authors' reply

artículo científico publicado en 2014

Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma

artículo científico publicado en 2016

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

artículo científico publicado en 2017

Biweekly paclitaxel and cisplatin in patients with advanced head and neck carcinoma. A phase II trial

artículo científico publicado en 1997

Breast cancer: diagnostic and therapeutic options

artículo científico publicado en 2004

Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study

artículo científico publicado en 2006

Cardiotoxic effects of anthracycline-taxane combinations.

artículo científico publicado en 2003

Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives

artículo científico publicado en 2018

Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies

artículo científico

Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer

artículo científico publicado en 2012

Clinical and pharmacological phase I evaluation of ExherinTM (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours

artículo científico publicado en 2009

Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex

artículo científico publicado en 2000

Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer

artículo científico publicado en 2004

Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?

artículo científico publicado en 2018

Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-the Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial

artículo científico publicado en 2018

Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.

artículo científico publicado en 2002

Correction: Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer

scientific article published on 01 February 2019

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

artículo científico publicado en 2018

Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition.

artículo científico publicado en 2006

Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies

scientific article published on 29 November 2006

Differences in O2 reduction by the iron complexes of adriamycin and daunomycin: the importance of the sidechain hydroxyl group

artículo científico publicado en 1986

Direct stimulation of ERBB2 highlights a novel cytostatic signaling pathway driven by the receptor Thr701 phosphorylation

artículo científico publicado en 2020

Dose-adjusting epirubicin in patients with altered liver function: when classical pharmacology makes good practical sense.

artículo científico publicado en 2003

Drugs ten years later: epirubicin.

artículo científico publicado en 1993

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

artículo científico publicado en 2012

Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies

artículo científico publicado en 2018

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

artículo científico publicado en 1994

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

artículo científico publicado en 2014

Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer

artículo científico publicado en 2017

Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer

artículo científico publicado en 2015

Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy

artículo científico publicado en 2005

Four-drug sequential regimen in advanced breast cancer.

artículo científico publicado en 1987

Future options with trastuzumab for primary systemic and adjuvant therapy

artículo científico publicado en 2004

Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer

artículo científico publicado en 2005

HER2-directed T-cell receptor-mimicking antibody: a "Me Too" or an example of novel antitumor aggressive mimicry?

artículo científico publicado en 2013

HER2-positive breast cancer

artículo científico publicado en 2016

Hallmarks of triple negative breast cancer emerging at last?

artículo científico publicado en 2014

High-dose chemotherapy for breast cancer: any use for it?

artículo científico publicado en 2002

Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer

scientific article published on 23 January 2017

Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer

scientific article published on 01 May 1997

Hydroxyl radical production and DNA damage induced by anthracycline-iron complex

scientific article published on 01 July 1984

Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial.

artículo científico publicado en 2015

Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors

artículo científico publicado en 2003

Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level

artículo científico publicado en 2004

Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968).

artículo científico publicado en 2015

International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010).

artículo científico

International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations

artículo científico publicado en 2003

Introducing new molecular technologies into routine clinical cancer care: is there an impact on the treatment of breast cancer?

artículo científico publicado en 2008

Is there room for another HER2-targeting drug?

artículo científico publicado en 2018

Ixabepilone and the narrow path to developing new cytotoxic drugs

artículo científico publicado en 2007

Learning from Cl-941 about pharmacokinetically guided dose escalation

artículo científico publicado el 1 de enero de 1992

Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours

artículo científico publicado en 2009

Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial

artículo científico publicado en 2013

Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.

artículo científico publicado en 2010

Monoclonal antibodies against doxorubicin

artículo científico publicado en 1988

Multidrug regimens for treatment of older patients with metastatic pancreatic cancer

artículo científico publicado en 2020

Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial

artículo científico publicado en 2018

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

artículo científico publicado en 2014

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

artículo científico publicado en 2010

Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study

artículo científico publicado en 2018

Never use anthracyclines with trastuzumab: it is time to reconsider the taboo

artículo científico publicado en 2009

Omega-3 Fatty Acids for Aromatase Inhibitor-Induced Musculoskeletal Pain: Anything Other Than a Placebo Effect?

scientific article published on 21 September 2015

Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative me

artículo científico publicado en 2010

Oxidative destruction of DNA by the adriamycin-iron complex.

artículo científico publicado en 1984

Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex

artículo científico publicado en 1982

PD-1 Inhibitors-Related Neurological Toxicities in Patients with Non-Small-Cell Lung Cancer: A Literature Review

article

Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies

artículo científico publicado en 2006

Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

artículo científico publicado en 1995

Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.

artículo científico publicado en 1995

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

artículo científico publicado en 2014

Pathological complete response in breast cancer--authors' reply

artículo científico publicado en 2015

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.

artículo científico publicado en 2012

Pharmacology and Clinical Toxicity of 4'-Iodo-4'-deoxydoxorubicin: An Example of Successful Application of Pharmacokinetics to Dose Escalation in Phase I Trials

article

Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma.

scientific article published on 12 July 2016

Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors

artículo científico publicado en 2014

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors

scientific article published on 07 March 2013

Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer.

artículo científico publicado en 2008

Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing

artículo científico publicado en 2006

Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule

artículo científico publicado en 2007

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

artículo científico publicado en 2002

Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours.

artículo científico publicado en 2008

Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas.

artículo científico publicado en 2018

Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

artículo científico publicado en 2010

Phase I/II study of gemcitabine in association with vinorelbine for metastatic breast cancer.

artículo científico publicado en 2001

Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin.

artículo científico publicado en 2004

Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.

artículo científico publicado en 2010

Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer

artículo científico publicado en 2009

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

artículo científico publicado en 2010

Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.

artículo científico publicado en 2009

Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer

artículo científico publicado en 2014

Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer

artículo científico publicado en 2003

Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease

artículo científico publicado en 2008

Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer.

artículo científico publicado en 2003

Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer

artículo científico publicado en 2010

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers

artículo científico publicado en 2013

Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer

artículo científico publicado en 2014

Report on the international colloquium on cardio-oncology (rome, 12-14 march 2014)

artículo científico publicado en 2014

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

article

Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables.

artículo científico publicado en 2001

Role of anthracyclines in the treatment of early breast cancer

artículo científico publicado en 2009

Role of daunosamine and hydroxyacetyl side chain in reaction with iron and lipid peroxidation by anthracyclines.

artículo científico publicado en 1988

Role of dose in the treatment of breast cancer.

artículo científico publicado en 2004

Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial

artículo científico publicado en 2018

Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study

artículo científico publicado en 2018

Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma.

artículo científico publicado en 2017

Seminars in clinical pharmacology: an introduction to MET inhibitors for the medical oncologist.

artículo científico

Sequence dependence of the antitumor and toxic effects of 5-fluorouracil and cis-diamminedichloroplatinum combination on primary colon tumors in mice ⬇️

artículo científico publicado el 1 de enero de 1988

Stereoselectivity of iododoxorubicin reduction in various animal species and humans

scientific article published on 01 February 1993

Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection

artículo científico publicado en 2018

Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer.

artículo científico publicado en 2015

Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.

artículo científico publicado en 2011

Surrogate markers for targeted therapy-based treatment activity and efficacy.

artículo científico publicado en 2011

Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine

artículo científico publicado en 2005

Targeting TRAIL agonistic receptors for cancer therapy.

artículo científico publicado en 2007

Targeting the epidermal growth factor receptor a new strategy in cancer treatment.

artículo científico publicado en 2002

Technology insight: Emerging techniques to predict response to preoperative chemotherapy in breast cancer

artículo científico publicado en 2004

The "other" signaling of trastuzumab: antibodies are immunocompetent drugs

scientific article published on 17 March 2008

The choice of the correct imaging modality in breast cancer management

artículo científico publicado en 2004

The cost of life: should it matter to doctors?

scientific article published on 01 March 2006

The future of targeted therapy: combining novel agents

artículo científico publicado en 2002

The immune system and response to HER2-targeted treatment in breast cancer

artículo científico

Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma

scientific article published on 10 March 2020

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

artículo científico publicado en 2005

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

artículo científico publicado en 2005

Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer

scientific article published on 23 December 2008

Trastuzumab emtansine for HER2-positive advanced breast cancer

artículo científico publicado en 2012

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

artículo científico publicado en 2017

Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience

artículo científico publicado en 2015

Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).

artículo científico publicado en 2014

Treatment of HER2-positive breast cancer: current status and future perspectives.

artículo científico publicado en 2011

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

artículo científico publicado en 2011

Triple-negative breast cancer: an unmet medical need

artículo científico publicado en 2011

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

artículo científico publicado en 2016

Triple-negative breast cancer: disease entity or title of convenience?

artículo científico publicado en 2010

Use of formalin-fixed paraffin-embedded samples for gene expression studies in breast cancer patients

artículo científico publicado en 2015

Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer

artículo científico publicado en 2009

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda